Interventional News’ top 10 most read articles of April 2022


top10A report from the American Venous Forum (AVF) 2022 meeting (23–26 February, Orlando, USA) on the comparative merits and demerits of dedicated and non-dedicated stents heads the list of Interventional News’ April top 10 articles. Some of the other most read pieces include the latest profile on Karim Valji, a conversation with Robert Hinchliffe, and a debate covering some of cancer treatment’s current controversies.


1) Researchers place venous stenting under the spotlight at AVF 2022

Venous stenting was a hot topic at the recent American Venous Forum (AVF) annual meeting (23–26 February, Orlando, USA). Catching the audience’s attention, Lilian Tran highlighted a head-to-head study of dedicated versus non-dedicated stents. 


2) Medtronic issues voluntary recall for subset of IN.PACT Admiral and IN.PACT AV DCBs due to pouch damage

Medtronic recently voluntarily recalled a subset of its IN.PACT Admiral and IN.PACT AV paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheters due to the potential for pouch damage resulting in a loss of sterility.


3) Profile: Karim Valji

Karim Valji is professor of radiology at the University of Washington (Seattle, USA) and professor Emeritus at the University of California, San Diego (USA) and speaks to Interventional News about his career.


4) CX 2022: A conversation with Robert Hinchliffe

Looking ahead to the CX Symposium, (which has now taken place: 26–28 April, London, UK) Robert Hinchliffe (University of Bristol, Bristol, UK) dubs the session on the “hurting leg” a highlight.


5) First patient enrolled in natural vascular scaffolding clinical trial

Alucent Biomedical announced in a press release that it has enrolled the first patient in ACTIVATE II, an Australia-based first-in-human clinical trial to evaluate the safety and efficacy of its natural vascular scaffolding (AlucentNVS) technology.


6) Truvic announces FDA 510(k) clearance for Prodigy thrombectomy system

Truvic Medical shared via press release that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for the Prodigy thrombectomy system, designed for the treatment of peripheral vascular thrombus.


7) Study finds increased risk of blood clots up to six months after COVID-19

A study from Sweden, published by The BMJ recently, finds an increased risk of deep vein thrombosis (DVT) up to three months after COVID-19 infection, pulmonary embolism (PE) up to six months, and a bleeding event up to two months.


8) SIO 2022: ‘Controversies’ in current cancer treatment

One of the key takeaways from the debate session at this year’s Society of Interventional Oncology (SIO) meeting (24–28 March, San Francisco, USA) was that radiation oncology has seen much innovation, and that this must continue in order to provide the best outcomes for patients into the future.


9) Cydar Medical announces strategic collaboration with Medtronic

Cydar Medical recently announced it has entered a strategic collaboration with Medtronic. Under the pilot arrangement, Cydar’s EV Maps software will be introduced to up to 40 new global sites, combining Cydar’s augmented intelligence technology with Medtronic’s services and case support.


10) Data from new VOYAGER PAD reinforce benefit of XARELTO

An analysis showed benefit of XARELTO plus aspirin in reducing thrombotic hospitalisations for peripheral arterial disease (PAD) patients with and without chronic kidney disease (CKD).


Please enter your comment!
Please enter your name here